Tesla has stopped production of its Model S and Model X vehicles to redirect factory capacity toward the Optimus humanoid robot program. The company is gearing up for limited sales and possible mass production of Optimus, while also planning an initial run of the Cybercab robotaxi. This shift accompanies growing legal and regulatory challenges related to the Cybercab name, Autopilot marketing, and full self-driving accident disclosures.
Tesla, listed as NasdaqGS:TSLA, is transitioning from its role as a primary electric vehicle manufacturer toward greater emphasis on robotics and artificial intelligence. Recent actions include halting production of the Model S and Model X to allocate factory resources to the Optimus humanoid robot initiative. The company anticipates limited sales of Optimus in the near term, with potential for mass production, and is preparing an initial production batch of the Cybercab robotaxi.
This repositioning occurs amid a share price of around $402.51, reflecting a 37.4% increase over the past year and more than doubling in value over the last three and five years. Analysts set a target price of $421.73, placing the current price about 5% below that level. However, Simply Wall St's valuation model indicates shares trade at approximately 207% above estimated fair value, with a price-to-earnings ratio of about 398x. The stock has experienced a roughly 6.7% decline over the past 30 days, amid market digestion of the robotics pivot and increasing legal scrutiny.
Tesla faces expanding legal and regulatory hurdles. These include disputes over the Cybercab name, actions concerning Autopilot marketing practices, and examination of disclosures related to full self-driving accidents. For investors, the combination of new product developments in Optimus and Cybercab, alongside these compliance issues, underscores the importance of execution and regulatory resolutions in the company's ongoing transition.
